Literature DB >> 26598581

Efficacy of Adjunctive High Frequency Repetitive Transcranial Magnetic Stimulation of Right Prefrontal Cortex in Adolescent Mania: A Randomized Sham-Controlled Study.

Vijay Pathak1, Vinod Kumar Sinha2, Samir Kumar Praharaj3.   

Abstract

OBJECTIVE: To examine the efficacy of adjunctive right prefrontal high-frequency repetitive transcranial magnetic stimulation (rTMS) treatment in adolescent mania patients as compared to sham stimulation.
METHODS: Twenty six right handed patients aged 12-17 years diagnosed with bipolar mania were randomized to receive daily sessions of active or sham rTMS (20 Hz, 110% of motor threshold, 20 trains, 10 s intertrain interval) over the right dorsolateral prefrontal cortex for 10 days. Mania was rated using Young Mania Rating Scale (YMRS) and Clinical Global Impression (CGI) at baseline, and after 5th and 10th rTMS.
RESULTS: For YMRS scores, repeated measures analysis of variance (ANOVA) showed a significant main effect (F=44.49, degree of freedom [df]=1.2/29.29, p<0.001, Greenhouse-Geisser corrected, effect size η(2)=0.65), but the interaction effect was not significant (F=0.03, df=1.2/29.29, p=0.912, Greenhouse-Geisser corrected). For CGI-Severity, repeated measures ANOVA showed a significant main effect (F=24.49, df=1.42/34.21, p<0.001, Greenhouse-Geisser corrected, effect size η(2)=0.51), but the interaction effect was not significant (F=0.06, df=1.2/29.29, p=0.881, Greenhouse-Geisser corrected).
CONCLUSION: High-frequency right prefrontal rTMS was found to be ineffective as add-on to standard pharmacotherapy in adolescent mania.

Entities:  

Keywords:  Adolescent; Bipolar disorder; Mania; Prefrontal cortex; Repetitive transcranial magnetic stimulation

Year:  2015        PMID: 26598581      PMCID: PMC4662165          DOI: 10.9758/cpn.2015.13.3.245

Source DB:  PubMed          Journal:  Clin Psychopharmacol Neurosci        ISSN: 1738-1088            Impact factor:   2.582


INTRODUCTION

Bipolar disorder affects young people with a lifetime prevalence of 1% among 14 to 18 year-olds.1) The therapeutic options available are limited by variable response, adverse effects and are not adequate for many patients. Transcranial magnetic stimulation (TMS) is a noninvasive method in which magnetic field over the surface of the head depolarizes underlying superficial neurons. Repetitive TMS (rTMS) has been found to inhibit or activate cortical areas which is frequency dependent; low-frequency rTMS (>1 Hz) has an inhibitory effect on cortical excitability and decreases blood flow, whereas high-frequency rTMS (>5 Hz) may lead to activation of cortical areas and increase blood flow.2) There are very few studies that have examined the efficacy of rTMS in children and adolescents, most of them have focused on depression, and some involves the treatment of the attention deficit hyperactivity disorder (ADHD), autism and schizophrenia.3–5) There are no major adverse events reported in these studies. High frequency rTMS has been studied for treatment of mania in adults in which improvements were reported after stimulating right prefrontal cortex. Grisaru et al.6) conducted a double-blind, controlled trial of right vs. left prefrontal rapid rTMS in 16 bipolar mania adult patients and found an improvement in manic symptoms with right rTMS and a worsening with left rTMS. In contrast, another controlled study by Kaptsan et al.7) using right prefrontal rapid rTMS in 19 bipolar mania patients, reported lack of therapeutic effect when compared to sham rTMS. Praharaj et al.8) in a randomized controlled study on a larger sample (n=41) found high-frequency supra-threshold right prefrontal rTMS was well tolerated and effective as add-on to standard pharmacotherapy in bipolar, mania patients. There are no published studies on the efficacy of rTMS in adolescent mania patients. Therefore, the current study was carried out to find the therapeutic efficacy and tolerability of add-on right prefrontal high-frequency (rapid) rTMS in adolescent mania patients.

METHODS

Participants

This was a prospective, hospital-based, single-blind, randomized, sham-controlled rTMS study carried out at the Centre for Cognitive Neurosciences, Central Institute of Psychiatry, Ranchi, India. The study was approved by the institutional review board. In this study, 26 right handed, normotensive patients of either sex, aged between 12–17 years with a diagnosis of bipolar disorder, mania according to Diagnostic Criteria for Research of International Classification of Diseases-109) were included in the study. Written informed consent was obtained from the parents prior to the study. Subjects with current neurological or any comorbid psychiatric disorders or history of drug abuse, past history of epilepsy, significant head injury or any neurosurgical procedure, with cardiac pacemakers or other metal parts in the body, or who have received electroconvulsive therapy in past 6 months were excluded from the study. The selected 26 patients were alternatively assigned to receive either active rTMS (n=13) or sham stimulation (n=13), with first patient receiving active treatment.

Tools

A semi-structured pro-forma was used for recording demographic and clinical details. The Hindi version of Handedness Preference Schedule10) which has 15 items was used to assess hand preference. The 11-item clinician administered Young Mania Rating Scale (YMRS)11) was used to assess severity of manic symptoms. Clinical Global Impression (CGI)12) was used to assess overall illness severity.

rTMS Procedure

The motor threshold (MT) for the right abductor pollicis brevis was determined using a figure-of-eight shaped coil at 1 Hz frequency according to Rossini-Rothwell algorithm.13) According to this algorithm, MT was defined as the lowest intensity, which produced 5 motor evoked potential (MEP) responses of at least 50 μV in 10 trials. The right prefrontal cortex rTMS stimulation site was determined by measuring 5 cm anterior and in a parasagittal line from the point of maximum stimulation of contralateral abductor pollicis brevis muscle.14) Daily sessions of 20 Hz rTMS (at 110% of MT, 2 seconds/train, 20 trains/session, 10 seconds intertrain interval, 800 pulses/day) was administered after one week using Magstim Rapid device over the right dorsolateral prefrontal cortex (DLPFC) for 10 days. The sham group was administered rTMS after the first week of admission using same parameters with one wing of the coil at 45° angle with the head; in this position TMS does not produce MEPs but does produce scalp sensations.2,14) The stimulation sessions were performed as ‘add on’ to the ongoing medications as decided by the treating team. YMRS and CGI were administered at baseline (on day 7) and after 5th and 10th rTMS sessions by the first author, VP. The investigators were blind to the medications received by the patients during the study period which were solely decided by the treating team, who were blind to the treatment condition. The patients were blind to the treatment condition.

Statistical Analysis

The data obtained was analyzed using Statistical Package for Social Sciences-version 16.0 for Windows (SPSS Inc., Chicago, IL, USA). Socio-demographic and clinical variables were compared using independent t-test and chi-square test, for continuous and categorical variables, respectively. To see the effect of treatment, the mean YMRS and CGI-Severity (CGI-S) scores were compared between active and sham group using two way repeated measures ANOVA. Greenhouse-Geiser correction was applied considering violation of sphericity assumption. Effect sizes were calculated for the effect of treatment. The proportion of patients in each group that achieved remission was determined using chi-square test. Remission was defined as a score of 12 or less in YMRS as used by Tohen et al.15)

RESULTS

Sample Characteristics

The socio-demographic and clinical profile of the active and sham group was comparable (Table 1). In the active group, 5 (38.5%) patients received lithium, 3 (23.1%) received carbamazepine, and 5 (38.5%) patients received valproate; whereas, in the sham group, 9 (69.2%) received lithium, 2 (15.4%) received carbamazepine, and 2 (15.4%) patients received valproate. There was no difference between the two groups. The mean motor threshold in the ac tive group was 61.92 (standard deviation [SD] 5.36) and in the sham group was 59.53 (SD 4.66); there was no difference between the two groups.
Table 1

Sample characteristics

CharacteristicGroupt/X2p value

Active (n=13)Sham (n=13)
Age (yr)15.38±1.8016.00±1.22−1.020.319
Education (yr)8.38±4.2110.76±2.48−1.750.092
Gender0.250.619
 Male10 (76.9)11 (84.6)
 Female3 (23.1)2 (15.4)
Socioeconomic status3.340.188
 Lower8 (61.5)9 (69.2)
 Middle5 (38.5)2 (15.4)
 Upper02 (15.4)
Habitat0.650.420
 Rural7 (53.8)9 (69.2)
 Urban6 (46.2)4 (30.8)
Family type1.750.185
 Nuclear8 (61.5)11 (84.6)
 Joint5 (38.5)2 (15.4)
Age of onset of illness (yr)14.04±2.5615.31±2.13−1.360.184
Duration of illness (yr)1.34±1.840.73±1.300.980.335
Total number of episodes1.38±2.560.38±0.511.370.181
Number of manic episodes1.07±2.210.15±0.371.480.152
Number of depressive episodes0.15±0.550.23±0.43−0.390.698
Duration of current episode (day)31.92±30.8844.76±33.66−1.010.321
Age at first hospitalization (yr)15.53±2.0215.15±4.030.310.762
Family psychiatric illness01
 Present9 (69.2)9 (69.2)
 Absent4 (30.8)4 (30.8)

Values are presented as mean±standard deviation or number (%).

*p<0.05 (2-tailed).

Effect of rTMS

The effect of rTMS on YMRS and CGI-S scores is shown in Table 2. For YMRS scores, repeated measures ANOVA showed a significant main effect (F=44.49, degree of freedom [df]=1.2/29.29, p<0.001, Greenhouse-Geisser corrected, effect size η2=0.65), but the interaction effect was not significant (F=0.03, df=1.2/29.29, p=0.912, Greenhouse-Geisser corrected). For CGI-S, repeated measures ANOVA showed a significant main effect (F=24.49, df=1.42/34.21, p<0.001, Greenhouse-Geisser corrected, effect size η2=0.51), but the interaction effect was not significant (F=0.06, df=1.2/29.29, p=0.881, Greenhouse-Geisser corrected). Among patients receiving add-on active rTMS 8 (61.5%) achieved remission in comparison to 6 (46.2%) patients receiving sham rTMS; the difference was not significant (χ2=0.62, p=0.431).
Table 2

Repeated measures ANOVA showing the effect of rTMS on YMRS and CGI-S in mania (n=26)

BaselineAfter 5th rTMSAfter 10th rTMSPillai’s trace Fp value
YMRS44.49**<0.001
 Active34.38±7.0423.46±10.4216.00±15.63
 Sham34.38±5.9123.69±7.7116.84±10.92
YMRS–group0.030.912
CGI-S24.49**<0.001
 Active4.84±0.804.15±1.063.38±1.61
 Sham4.92±0.644.07±0.863.38±1.55
CGI-S–group0.060.881

Values are presented as mean±standard deviation.

p<0.001 (2-tailed).

ANOVA, analysis of variance; rTMS, repetitive transcranial magnetic stimulation; YMRS: Young Mania Rating Scale; CGI-S: Clinical Global Impression-Severity.

Adverse Effects of rTMS

There was no report of any serious side effect including seizure in patients receiving rTMS or sham treatment. The most common complaint of the patients receiving active treatment was pain during delivery of the train of stimulation which improved spontaneously after completion of the session. Transient headache was reported by 2 patients (15.4%) receiving active treatment following rTMS session, which lasted from less than an hour to four hours.

DISCUSSION

The findings in our study showed that high-frequency rTMS over right prefrontal cortex was not effective in bipolar mania in adolescents. This is in contrast to the findings from the studies in adults,6,8) which reported improvement in manic symptoms with similar stimulation parameters. It was hypothesized that there is a decreased anterior metabolism (hypofrontality) that is more pronounced on the right side and a relative increase in metabolism is present on the left side in patients with mania, which is the opposite of what is observed in depression.6) The improvements have been suggested to occur as a result of correcting the altered metabolism or blood flow that is associated with mania.8) The lack of effect in our study could possibly indicate that the pattern of abnormalities in blood flow or metabolism observed in adolescents be different than that of adults.16) Recent studies have found high-frequency rTMS to be effective in adolescent depression.17–19) Another reason for the lack of efficacy of rTMS in our study could be the use of lower doses (800 pulses/day) in the current study, as some of the recent studies have used 2,000 to 3,000 pulses/day,19–21) albeit for indications other than mania. Indeed, another strategy that have used 15,000 pulses/day over 2 days (‘accelerated rTMS’) in depressed patients found it to be both safe as well as effective,22) which suggests aggressive treatment with higher dose may be equally effective alternatives to traditional rTMS approaches. In our study, rTMS was well tolerated without any emergent serious adverse effects such as seizure. It can be concluded from our study that rTMS can be administered safely in adolescents using similar parameters as in the adults. The sample size was larger than previous studies in adolescent population.3–5,18,19) As the rTMS parameters are not standardized yet, further studies need to be done using different parameters in adolescent mania population. The limitations of the study included lack of double blinding which could lead to rater bias during the assessment of psychopathology. Alternative assignment of the patients to either treatment group does not represent true randomization is another limitation. The DLPFC of patients was located using the “5 cm rule”, which does not take into consideration the shape and size of a person’s head.23) This may result in some variations in the exact site of stimulation in the prefrontal cortex. Further studies may be conducted with precise localization under neuroimaging guidance.
  20 in total

1.  Transcranial magnetic stimulation in adolescent depression.

Authors:  Colleen Loo; Tara McFarquhar; Garry Walter
Journal:  Australas Psychiatry       Date:  2006-03       Impact factor: 1.369

Review 2.  Applications of transcranial magnetic stimulation (TMS) in child and adolescent psychiatry.

Authors:  Paul E Croarkin; Christopher A Wall; Jon Lee
Journal:  Int Rev Psychiatry       Date:  2011-10

3.  A rating scale for mania: reliability, validity and sensitivity.

Authors:  R C Young; J T Biggs; V E Ziegler; D A Meyer
Journal:  Br J Psychiatry       Date:  1978-11       Impact factor: 9.319

Review 4.  Emerging biosignature of brain function and intervention in pediatric bipolar disorder.

Authors:  T Mayanil; E Wegbreit; J Fitzgerald; M Pavuluri
Journal:  Minerva Pediatr       Date:  2011-06       Impact factor: 1.312

5.  Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression.

Authors:  Paul E Holtzheimer; William M McDonald; Mustafa Mufti; Mary E Kelley; Sinéad Quinn; German Corso; Charles M Epstein
Journal:  Depress Anxiety       Date:  2010-10       Impact factor: 6.505

Review 6.  Transcranial magnetic stimulation in persons younger than the age of 18.

Authors:  Humberto Quintana
Journal:  J ECT       Date:  2005-06       Impact factor: 3.635

7.  Transcranial magnetic stimulation (TMS) in the treatment of attention-deficit/hyperactivity disorder in adolescents and young adults: a pilot study.

Authors:  Laurel Weaver; Anthony L Rostain; William Mace; Umair Akhtar; Edward Moss; John P O'Reardon
Journal:  J ECT       Date:  2012-06       Impact factor: 3.635

8.  Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Authors:  M Tohen; T G Jacobs; S L Grundy; S L McElroy; M C Banov; P G Janicak; T Sanger; R Risser; F Zhang; V Toma; J Francis; G D Tollefson; A Breier
Journal:  Arch Gen Psychiatry       Date:  2000-09

9.  Decrease of middle cerebral artery blood flow velocity after low-frequency repetitive transcranial magnetic stimulation of the dorsolateral prefrontal cortex.

Authors:  Jens D Rollnik; Ariane Düsterhöft; Jan Däuper; Andon Kossev; Karin Weissenborn; Reinhard Dengler
Journal:  Clin Neurophysiol       Date:  2002-06       Impact factor: 3.708

Review 10.  The emerging role for repetitive transcranial magnetic stimulation in optimizing the treatment of adolescent depression.

Authors:  Paul E Croarkin; Christopher A Wall; Shawn M McClintock; Frank Andrew Kozel; Mustafa M Husain; Shirlene M Sampson
Journal:  J ECT       Date:  2010-12       Impact factor: 3.635

View more
  4 in total

Review 1.  Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature.

Authors:  Corey H Allen; Benzi M Kluger; Isabelle Buard
Journal:  Pediatr Neurol       Date:  2017-01-04       Impact factor: 3.372

2.  Mapping mania symptoms based on focal brain damage.

Authors:  Gonçalo Cotovio; Daniel Talmasov; J Bernardo Barahona-Corrêa; Joey Hsu; Suhan Senova; Ricardo Ribeiro; Louis Soussand; Ana Velosa; Vera Cruz E Silva; Natalia Rost; Ona Wu; Alexander L Cohen; Albino J Oliveira-Maia; Michael D Fox
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

3.  Treatment of mixed depression with theta-burst stimulation (TBS): results from a double-blind, randomized, sham-controlled clinical trial.

Authors:  Diego Freitas Tavares; Paulo Suen; Carla Garcia Rodrigues Dos Santos; Doris Hupfeld Moreno; Leandro Da Costa Lane Valiengo; Izio Klein; Lucas Borrione; Pamela Marques Forte; André R Brunoni; Ricardo Alberto Moreno
Journal:  Neuropsychopharmacology       Date:  2021-06-30       Impact factor: 7.853

Review 4.  Clinical applications of transcranial magnetic stimulation in bipolar disorder.

Authors:  Alexandra K Gold; Ana Claudia Ornelas; Patricia Cirillo; Marco Antonio Caldieraro; Antonio Egidio Nardi; Andrew A Nierenberg; Gustavo Kinrys
Journal:  Brain Behav       Date:  2019-09-30       Impact factor: 2.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.